ZNF180

Across TCGA pan-cancer cohorts, ZNF180 Mutation is linked to patient survival in 9 of 34 cancer types, making it a survival-associated ZNF180 data layer compared with 22 for mass-spec protein and 3 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher ZNF180 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated ZNF180 expression acts as an unfavorable survival marker, although some lineages such as UCEC and LUSC show a favorable association.

KIRP, LUAD, and READ are the cancer types where ZNF180 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	II,III,IV	0.127	0.859	<.001	37	view →
LUAD	OS	Median	II,III,IV	0.227	0.711	.002	16	view →
READ	DFS	Median	III,IV	0.255	0.757	.008	15	view →
UCEC	DFS	Median	II,III,IV	0.922	0.479	.027	14	view →
SARC	DFS	Median	All	0.153	0.613	.011	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
SKCM	OS	Median	III,IV	0.138	0.841	<.001	6	view →
BRCA	DFS	Median	II,III,IV	0.182	0.520	.049	2	view →
LUSC	OS	Median	All	0.887	0.391	.018	2	view →

Pink = unfavorable, green = favorable. Showing the 9 strongest of 9 lineages.

ZNF180–KIRP (OS)

Open the KIRP breakdown →